Director at Hologic (NASDAQ: HOLX) receives 3,190 stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.

Hologic director Martin D. Madaus reported an equity award of 3,190 restricted stock units of common stock on February 26, 2026. These units vest on the date of the 2027 Annual Meeting of Stockholders and are settled one-for-one in Hologic common shares.

After this grant, Madaus directly holds 5,396 common shares. A separate line shows indirect ownership of 5,445 common shares through a revocable trust, reflecting his holdings in that entity.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Madaus Martin D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,190	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,396 shares (Direct); Common Stock — 5,445 shares (Indirect, Revocable Trust)

Footnotes (1)

Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Restricted stock units are settled in shares of common stock on a one-for-one basis.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/02/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Madaus Martin D

(Last)

(First)

(Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH

01752

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		3,190⁽¹⁾	A	⁽²⁾	5,396	D
Common Stock								5,445	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

	/s/ Mark W. Irving, attorney-in-fact for Mr. Madaus	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Hologic (HOLX) report for Martin D. Madaus?

Hologic reported that director Martin D. Madaus received 3,190 restricted stock units of common stock. The award was dated February 26, 2026 and represents equity-based compensation rather than an open-market stock purchase or sale.

When do Martin D. Madaus’s new Hologic (HOLX) restricted stock units vest?

The 3,190 restricted stock units granted to Martin D. Madaus vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. Vesting ties the award to continued board service through that shareholder meeting.

How are the Hologic (HOLX) restricted stock units held by Martin D. Madaus settled?

The restricted stock units are settled in Hologic common stock on a one-for-one basis. This means each unit converts into one share of common stock upon vesting at the 2027 Annual Meeting of Stockholders.

How many Hologic (HOLX) shares does Martin D. Madaus own directly after this Form 4?

Following the grant, Martin D. Madaus directly holds 5,396 shares of Hologic common stock. This total reflects his direct ownership position after including the newly reported restricted stock unit award.

What indirect Hologic (HOLX) holdings does Martin D. Madaus report through a revocable trust?

The filing shows an indirect position of 5,445 Hologic common shares held through a revocable trust. This reflects shares attributed to Madaus via that trust structure, separate from his directly held shares.

Is the Hologic (HOLX) Form 4 for Martin D. Madaus a stock purchase or sale?

The Form 4 reflects an acquisition through a grant of 3,190 restricted stock units, not a market purchase or sale. The units were awarded at no stated price as equity compensation for board service.